CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) revealed that it is partnering with licensed producer and multi-state operator Vireo Health International to support a clinical trial for medical cannabis treatments in the US.
It marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management.
The study will focus on Vireo’s line of products, which are currently available in Minnesota but are scheduled to launch in other markets this year.
CB2 Insights will manage the process of designing the protocol and working with the FDA on IND (Investigational New Drug) application approval. The initial stage of the project is earmarked to be completed by the first quarter of 2020.
"As we have seen with the FDA over the past year, they are steadfast in ensuring that cannabis-based medicines follow the same protocols as other traditional pharmaceuticals," said Prad Sekar, CEO of CB2 Insights.
"We are proud to have been chosen to advance that process with Vireo as we move forward with the IND application."
Vireo will also license CB2 Insights' cloud-based data-analytics platform 'Sail' for full data collection and management, the firm said in Tuesday's statement.
CB2 Insights has active technology, data and research projects in North America, the UK and Colombia.
It can support licensed producers, multi-state operators from pre-clinical trial activities through to product commercialization.
The company operates the largest multi-state cannabis evaluation and education centers in the US, overseeing the care of more than 100,000 patients.
Sharesd added 4% to stand at C$0.13 in Toronto.
Contact the author at [email protected]